From last week. I just read it (as usual, I won't re-post copyright material). By Matthew Roden. Very nice dynamic valuation of Incyte (a lot of people like to see such things, but you've read my opinions before). He makes an interesting point in conjunction with the PaCa results: the survival benefit is interesting and a bit unexpected. I, at least, had been dividing probabilities between anti-tumor activity of Ruxo and postponement of death by wasting. Roden suggests that by combatting the side effects of the drug it was paired with, Ruxo allowed more patients to stay on (effective) treatment. The potential nice feature here is that effective anti-cancer drugs do tend to have [sometimes dose-limiting] inflammatory side effects, so we have another activity that may not be restricted to one of a few tumor types.